Nuvectis Pharma, Inc. (NASDAQ:NVCT) Financings

Nuvectis Pharma, Inc.

Financings

RaiseDate
Public offering of shares (follow-on public offering)
Closed: US$115M raised
Use of proceeds: Advance development of NXP100 in PNH and other complement-mediated diseases and the oncology portfolio
Aug 4, 2026
Public offering of common stock
Update: US$100M · US$20 a share · Cantor +6
Dealers: Cantor (lead), H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, Titan Partners, a division of American Capital Partners
Use of proceeds: Advance NXP100, NXP200 and NXP900 programs, hiring, capital expenditures, public company costs and general corporate purposes
Jun 30, 2026
At-the-market programme of shares
Closed: at-the-market programme
Aug 5, 2025
Public offering of common stock
Closed: US$15.5M raised · US$5 a share · Lucid Capital Markets
Dealers: Lucid Capital Markets (lead)
Use of proceeds: Advance NXP800 and NXP900 development, hiring, capital expenditures, public company costs and general corporate purposes
Feb 7, 2025

Read by 6ix AI from the company's releases